Skip to main content

Table 3 Correlation analysis of clinical characteristics between the PD-CI and VaP-CI groups and control group; M (P25-P75)

From: The correlation between enlarged perivascular spaces and cognitive impairment in Parkinson’s disease and vascular parkinsonism

Variable

PD-CI group (n = 16)

VaP-CI group (n = 16)

Control group (n = 32)

P values

Age, years

63.00 (58.00–70.75) ^

75.50 (69.50–80.75) ^

48.50 (37.50–57.00)

 < 0.001***

BG-EPVS numbers

9.00 (7.00–12.00)

15.50 (10.25–30.50) ^

7.00 (4.00–8.00)

 < 0.001***

CSO-EPVS numbers

18.00 (9.50–23.50) ^

18.00 (7.75–26.00) ^

8.00 (4.25–13.00)

0.001**

EPVS I as the main type, n (%)

3 (18.80)

9 (56.30)

10 (31.30)

0.072

Fazekas scores

0.00 (0.00–1.00) ^

2.00 (1.00–3.75) ^

0.00 (0.00–0.00)

 < 0.001***

GCA scores

1.00 (0.25–2.00) ^

3.00 (2.00–3.00) ^

0.00 (0.00–0.00)

 < 0.001***

KS scores

2.00 (1.00–3.00) ^

3.00 (2.25–3.00) ^

0.00 (0.00–0.00)

 < 0.001***

MTA scores

1.00 (0.00–2.00) ^

2.50 (1.00–3.75) ^

0.00 (0.00–0.00)

 < 0.001***

Lacunes numbers

0.00 (0.00–2.75) ^

2.00 (0.25–5.50) ^

0.00 (0.00–0.00)

 < 0.001***

CMBs numbers

0.00 (0.00–1.00)

1.50 (1.00–5.75) #

-

0.002**

UPDRS-III scores “OFF”

42.50 (30.25–45.00)

50.00 (33.50–55.00)

-

0.076

H-Y stages

3.00 (2.00–4.00)

4.00 (3.00–4.75) #

-

0.031*

Duration of onset to enrolment, years

1.00 (0.50–2.75)

3.50 (1.25–6.00)

-

0.155

  1. *P < 0.05, **P < 0.01, ***P < 0.001. Compared to the control group, ^adjusted P < 0.017. Compared to the PD-CI group, adjusted P < 0.017, #P < 0.05